CELL BIOLOGY AND TOXICOLOGY, published by SPRINGER, stands as a vital journal within the realms of cell biology and toxicology, boasting an impressive 2023 Q1 ranking in its fields, alongside robust Scopus rankings placing it in the top 11th percentile for Toxicology and the 22nd for Health, Toxicology and Mutagenesis. With an ISSN of 0742-2091 and an E-ISSN of 1573-6822, the journal has been a cornerstone of scientific discourse since its inception in 1984, and will continue to converge innovative research until 2024. The journal focuses on the interplay between cellular mechanisms and toxicological implications, making it an essential resource for researchers, healthcare professionals, and students keen on advancing their understanding of these critical areas. Although it does not offer open access, its high impact and prestigious standing ensure that its publications reach a wide audience dedicated to significant advancements in the life sciences.

The International Journal of Biochemistry & Cell Biology, published by Pergamon-Elsevier Science Ltd, stands as a pivotal resource in the fields of biochemistry and cell biology. With an ISSN of 1357-2725 and an E-ISSN of 1878-5875, this prestigious journal has been a key platform for disseminating cutting-edge research since its inception in 1995. The journal currently holds an impressive Q1 ranking in Biochemistry and a Q2 ranking in Cell Biology for the year 2023, reflecting its commitment to high-quality research and its influence within the scientific community. With a significant Scopus ranking of 94/438 in Biochemistry and 96/285 in Cell Biology, the journal plays a crucial role in advancing knowledge and fostering innovative approaches in these dynamic fields. Though it is not an open-access journal, the International Journal of Biochemistry & Cell Biology remains accessible to a wide audience, making it a vital resource for researchers, professionals, and students alike, who are eager to explore and contribute to the ongoing advancements in biochemistry and cell biology.

CELL CYCLE, an esteemed journal published by Taylor & Francis Inc., stands at the forefront of biological research, focusing on the intricate mechanisms of cell proliferation, molecular biology, and developmental biology. With an ISSN of 1538-4101 and an E-ISSN of 1551-4005, this journal has established its influence in the field with a commendable impact factor reflecting its rigorous peer-review process and high-quality publications. Notably, in 2023, it achieved a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in both Cell Biology and Developmental Biology, marking its vital role in advancing scientific understanding and innovation. Operating within a converged framework from 2002 to 2024, CELL CYCLE caters to a diverse audience of researchers, professionals, and students eager to explore contemporary findings and emerging trends. The journal's objective is to disseminate groundbreaking research that enhances our understanding of cellular mechanisms, fostering collaboration and innovation. Although not an open-access journal, it remains a premier source for those engaged in cell cycle research, and its contributions have significant implications for fields such as healthcare, biotechnology, and genetics.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

CELLULAR AND MOLECULAR LIFE SCIENCES, published by SPRINGER BASEL AG, stands as a premier journal dedicated to advancing the field of cellular and molecular biology. With an impressive 2023 impact factor reflected in its Q1 rankings across key categories—including Cell Biology, Molecular Biology, and Pharmacology—it serves as a critical platform for researchers aiming to disseminate high-quality findings in these dynamic fields. Operated under an open access framework, the journal allows broader accessibility to groundbreaking research, fostering collaboration amongst scientists globally. Based in Switzerland, CELLULAR AND MOLECULAR LIFE SCIENCES has been at the forefront of scientific publishing since 1952, adapting to contemporary scientific challenges and trends, ultimately shaping the future of life sciences.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS is a vital academic journal published by Taylor & Francis Inc, dedicated to the intricate and evolving domains of biochemistry, genetics, and molecular medicine. With an ISSN of 1525-7770 and E-ISSN of 1532-2335, this journal aims to provide a comprehensive platform for the dissemination of research findings, reviews, and methodologies related to nucleosides, nucleotides, and nucleic acids. As a research journal thriving since its inception in 2000, it reflects a diverse spectrum of studies crucial for advancing knowledge in biochemistry (ranked Q4) and genetics (Q4), while also achieving Q3 status in medicine (miscellaneous). Despite its current standing in the quartiles and Scopus rankings indicative of an emergent trajectory, the journal retains significant relevance for those delving into interdisciplinary research that intersects these fields. Researchers, professionals, and students alike can explore a plethora of original research articles, thought-provoking reviews, and updates on pioneering advances that shape our understanding of molecular biology. With its unwavering commitment to scholarly excellence, NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS continues to be an essential resource for those aiming to contribute to and stay informed about this pivotal area of scientific inquiry.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.